Literature DB >> 9303387

Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.

H Thadepalli1, S K Chuah, U Reddy, N Hanna, R Clark, R J Polzer, S Gollapudi.   

Abstract

We investigated the efficacy of trovafloxacin, a new quinolone, in comparison with that of clindamycin in the treatment of intra-abdominal abscesses caused by Bacteroides fragilis in young and senescent mice. The development of abscess formation, the number of viable organisms, and antibiotic concentrations were measured, and the values for young and old mice were compared. Trovafloxacin was well distributed to the tissues in both young and old animals. Although the pharmacokinetics and concentrations of trovafloxacin in serum were similar between young and old mice, the levels in tissue were higher in senescent mice than in young mice. Trovafloxacin therapy sterilized abscesses in 94% of young mice and in 73% of old mice, but this difference was not significant. This therapeutic response to trovafloxacin was similar to that seen with clindamycin. These results suggest that aging may not have any adverse effect on the therapeutic outcome for intra-abdominal abscesses caused by B. fragilis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303387      PMCID: PMC164038          DOI: 10.1128/AAC.41.9.1933

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Altered cellular responsiveness during ageing.

Authors:  S I Rattan; A Derventzi
Journal:  Bioessays       Date:  1991-11       Impact factor: 4.345

Review 2.  Antibiotics at the extremes of age: choices and constraints.

Authors:  D A Lewis; D S Reeves
Journal:  J Antimicrob Chemother       Date:  1994-08       Impact factor: 5.790

3.  Age-related decline in the resistance of mice to infection with intracellular pathogens.

Authors:  I D Gardner; J S Remington
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

4.  Use of lymphokines in treatment of experimental intra-abdominal abscess caused by Bacteroides fragilis.

Authors:  S V Gollapudi; A Gupta; H Thadepalli; A Perez
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

5.  Appendicitis in the elderly.

Authors:  B J Owens; H F Hamit
Journal:  Ann Surg       Date:  1978-04       Impact factor: 12.969

6.  Age-dependent differences in outcome of infections, with special reference to experiments in mice.

Authors:  D B Louria; P Sen; M Buse
Journal:  J Am Geriatr Soc       Date:  1982-12       Impact factor: 5.562

7.  Studies in the distribution of body fat: I. Effects of age, sex, and obesity.

Authors:  H Shimokata; J D Tobin; D C Muller; D Elahi; P J Coon; R Andres
Journal:  J Gerontol       Date:  1989-03

8.  Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 9.  Biopharmaceutical aspects of anti-infective therapy at the extremes of age.

Authors:  H G Schaefer; J Michaelis
Journal:  J Antimicrob Chemother       Date:  1994-08       Impact factor: 5.790

10.  In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.

Authors:  I Brook
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  4 in total

1.  In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.

Authors:  L E Stearne; I C Gyssens; W H Goessens; J W Mouton; W J Oyen; J W van der Meer; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.

Authors:  Alan R Noel; Karen E Bowker; Alasdair P Macgowan
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines.

Authors:  Taly Weiss; Itamar Shalit; Hannah Blau; Sara Werber; Drora Halperin; Avital Levitov; Ina Fabian
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 4.  Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.

Authors:  Temilolu Idowu; Frank Schweizer
Journal:  Antibiotics (Basel)       Date:  2017-11-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.